Zoster Eye Disease Study (ZEDS) Results
Elisabeth Cohen MD Bennie Jeng MD Andrea Troxel ScD Judith Hochman MD NYU Langone Health Zoster Eye Disease ... Department of Ophthalmology
Adult Cardiac Surgery | NYU Langone Health
NYU Langone’s cardiac surgeons perform heart surgery, including heart valve procedures, for adults with heart-related conditions.
NYU Langone Transplant Institute | NYU Langone Health
Experts at the NYU Langone Transplant Institute specialize in heart, kidney, liver, lung, and pancreas transplantation.
Obstetrics & Gynecology | NYU Langone Health
At NYU Langone, our obstetrician–gynecologists provide experienced and compassionate care to people of all ages and gender identities.
24-Hour Activity and Cardiometabolic Health in Chinese American Women with a History of Gestational Diabetes
Chinese Americans, one of the largest and fastest-growing minority groups in the US, have an increased risk for type 2 diabetes (T2D) and a substantial burden related to T2D. Moreover, Chinese American women experience high rates of gestational diabetes (GD). However, little is known about the 24-hour activity (physical activity, sedentary behavior, sleep) and cardiometabolic health of Chinese American women with a history of GD. The objectives of this mixed methods study are to characterize the 24-hour activity and cardiometabolic risk profile and to describe the multi-contextual barriers and facilitators to meeting physical activity and sleep guidelines in this high-risk population. This pilot feasibility study using a convergent mixed methods design will collect accelerometer-based data, surveys, biomarker data, and conduct in-depth interviews with a sample of 56 Chinese American women with a history of GD in the past 0.5 - 5 years. Participants (n=56) will be recruited from NYU Langone Health System, online via WeChat (a Chinese social media app), and in person in Chinese community centers. Accelerometers (Actigraph GT9X+) will be used to collect 7 consecutive days of 24-hour activity. Validated instruments (online) will be used to assess psychological, social, cultural, and environmental characteristics. Biomarker data (glucose regulation and lipid profile) collection and in-depth interviews will be conducted in person. Descriptive analysis will be used to describe the sample, their 24-hour activity pattern, and their cardiometabolic risk profile. Quantitative and qualitative data will be integrated in the final analytic stage to identify modifiable factors for meeting physical activity and sleep guidelines.In addition,
320+ locations and 6,000 doctors—always nearby | NYU Langone Health
NYU Langone has more than 300 locations & 4,000 doctors throughout New York City, Westchester County, Long Island, and Florida.
3D Free-Breathing Fat and Iron Corrected T1 Mapping
This study proposes a novel 3D liver T1 mapping technique that will enable water-specific T1 mapping (or fat/iron-corrected T1 mapping) to remove the influence of both fat and iron, two confounding factors that have typically been neglected in standard T1 mapping. In a pilot study, we will test the performance of the proposed method for evaluating nonalcoholic steatohepatitis (NASH).
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
This study will be a multi-site, double-blind, randomized clinical trial of the 5-HT2A receptor agonist psilocybin for smoking cessation. The current trial will be conducted across three sites with experience in conducting psilocybin research: Johns Hopkins University (JHU), the University of Alabama at Birmingham (UAB), and New York University Grossman School of Medicine (NYU). The proposed double-blind study will treat 66 participants (22 at each site), randomized to receive either: 1) oral psilocybin; 30 mg in session 1 and either 30 mg or 40 mg in session 2, with sessions 1 week apart (total 2 drug exposures separated by approximately one week); or 2) oral niacin; 150 mg in session 1 and either 150 mg or 200 mg in session 2, with sessions 1 week apart (total 2 drug exposures separated by approximately one week).
<strong>Adolescents:</strong> A Prospective Single Arm Open Label Trial to Confirm Safety and Effectiveness of Prism as an Adjunct to Standard of Care in Adolescents with Post-Traumatic Stress Disorder (PTSD)
The purpose of this research study is to is to establish if the FDA-approved Prism device, currently used for treating adult PTSD patients can also be safely used to help adolescents. For more information, please email TeenPTSDTxStudy@nyulangone.org.
A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)
This is a 2-part seamless, randomized, double-blind, placebo-controlled, multicenter, Phase 2/3 study designed to evaluate the efficacy and safety of BIIB059 for the treatment of participants with active SCLE and/or CCLE with or without systemic manifestations and refractory and/or intolerant to antimalarial therapy. The study includes a Part A (Phase 2) and a Part B (Phase 3 registrational). The study comprises a 24-week DBPC treatment period followed by a 28-week ETP; the total treatment duration of 52 weeks.Participants who successfully complete the 52-week treatment period will be offered the opportunity to participate in an LTE study under a separate protocol. The LTE study will evaluate the long-term safety profile of BIIB059 in the treatment of CLE.Participants will be randomly assigned in a 2:1 ratio to receive either BIIB059 or placebo SC Q4W, respectively, from Week 0 to Week 20, with an additional loading dose at Week 2 during the DBPC period.During the ETP, all participants will receive BIIB059 from Week 24 to Week 48. At Week 26, participants will receive a loading dose where all participants who were randomly assigned to BIIB059 during the DBPC period will receive the placebo and all participants who were randomly assigned to placebo during the DBPC period will receive BIIB059.